Researchers are discovering how ketamine—a drug traditionally used for anesthesia—has gained a surprising role as a rapid and effective antidepressant. At low doses, a single administration of ketamine can lift depressive symptoms within hours, providing relief that lasts for days, even in cases where conventional antidepressants have failed. But how exactly does ketamine achieve these profound effects? A recent study offers new insights, focusing on how ketamine helps restore damaged brain cell connections, specifically in regions affected by chronic stress and depression.

Over the past few decades, ketamine has emerged as a groundbreaking treatment for depression, especially for those who haven’t found relief with traditional methods. Originally an anesthetic, ketamine’s unique brain effects make it one of the few drugs able to rapidly reduce symptoms of depression in hours. A recent study sheds new light on how ketamine achieves this, targeting specific areas of the brain in a way that could lead to more precise and effective depression treatments.

For people with major depressive disorder (MDD), especially those with recurrent episodes, managing symptoms can be a constant struggle. Suicidal thoughts, a dangerous and common symptom, affect about two-thirds of those with MDD. Traditional antidepressants can take weeks or even months to show effects, and for some, they don’t work at all. But recently, ketamine has emerged as a potential game-changer.

Well3 is introducing a flat rate ketamine therapy program, designed to make treatment more straightforward and affordable for patients. By offering clear pricing based on the type and amount of ketamine administered, the new program ensures that individuals seeking mental health support through ketamine can better plan for their treatment costs.

Well3 is proud to unveil a new flat rate weight loss program, offering simplified pricing based on the amount of medicine required. This initiative is designed to make weight loss treatments more affordable and accessible, especially for individuals with modest weight loss goals.

In light of ongoing developments surrounding GLP-1 medications like Mounjaro and Zepbound, we want to update you on our approach to maintaining access to tirzepatide. As highlighted in the recently on the challenges of supply and demand, there have been significant disruptions in the availability of these medications. However, we are actively working with compounding pharmacies to ensure that we can meet patient needs and avoid the common hurdles seen in recent months.

Ketamine and psilocybin, two substances often discussed in the context of mental health, are making waves in the treatment of conditions like depression and substance use disorder (SUD). These drugs not only work quickly compared to traditional antidepressants, but they also produce powerful changes in how people perceive the world around them. Researchers are starting to ask: Do these "mind-altering" experiences actually help people get better?

In recent years, ketamine has gained recognition as a promising treatment for mental health conditions like depression, anxiety, and PTSD, particularly for patients who haven’t found relief through traditional antidepressants. But what exactly makes ketamine different, and how does it compare to conventional medications like SSRIs and SNRIs? Here's what you need to know.

When your hormones are off, when you’re carrying excess weight, or when your mind is overwhelmed, it’s hard to even imagine what feeling good looks like. That’s when you need to find your own metaphorical hot tub—a way to experience what feeling good is like, even if just for a moment, to remind you that the effort to get there is worth it.

The growing popularity of medications like Ozempic (semaglutide) and Wegovy (another version of semaglutide) for weight loss has brought attention to their ability to help individuals shed pounds and maintain healthier lifestyles. Recently, another medication, tirzepatide (marketed as Mounjaro for type 2 diabetes), has also shown promise for weight management. However, what is less frequently discussed is how these medications can be seen as tools rather than lifelong solutions.

Alcohol use disorder (AUD) is a significant public health issue, affecting millions of adults worldwide, including in the United States. Despite the widespread nature of this problem, only about 20% of those with alcohol issues receive treatment, and the success rate for long-term sobriety remains low. Approximately 75% of individuals who quit drinking relapse within a year. The consequences of AUD extend beyond the individual, impacting families, communities, and society at large. The financial burden on healthcare systems is substantial, with costs estimated in the billions. In response to this pressing issue, researchers in the United Kingdom are conducting the MORE-KARE study to explore the potential of ketamine-assisted psychological therapy to improve treatment outcomes for individuals with severe alcohol use disorder.

Ketamine, a dissociative anesthetic developed in the 1960s, has gained renewed interest in recent years for its potential in treating mental health conditions such as depression, anxiety, and PTSD. Unlike traditional antidepressants, which can take weeks to show effects, ketamine often provides rapid relief. Here are three stories of individuals who have found success with ketamine treatment.

Depression is a significant global health issue, and for those with treatment-resistant depression (TRD), finding an effective treatment can be a daunting challenge. A recent study published in JAMA Network Open sheds light on the benefits of two major treatments for TRD: Ketamine and Electroconvulsive Therapy (ECT). This study provides critical insights that can help patients and healthcare providers make more informed decisions.

Ketamine, a medication traditionally used as an anesthetic, has gained attention for its rapid-acting antidepressant effects, particularly for those struggling with treatment-resistant depression (TRD). Unlike typical antidepressants that can take weeks to show benefits, ketamine often works within hours. However, the effects of a single dose are usually short-lived, leading doctors to develop multidose treatment plans to extend the benefits.

Sugar, particularly in its refined form, is one of the most harmful ingredients in our diet today. High consumption of sugar is linked to a slew of health issues, including obesity, type 2 diabetes, heart disease, and dental decay. It induces rapid spikes in blood glucose and insulin levels, playing a crucial role in metabolic syndrome—a cluster of conditions that heightens the risk of heart disease and other health problems. Additionally, sugar contributes to inflammation and is linked to the aging process and the onset of certain cancers.

In a groundbreaking study published in Nature, a recent phase 2 clinical trial has brought new hope for patients suffering from treatment-resistant depression (TRD). The trial tested the efficacy and safety of extended-release ketamine tablets (R-107) and presented promising results that could significantly alter the landscape of depression treatment.

Depression, a multifaceted mental health disorder, affects millions worldwide. While traditional antidepressants like SSRIs, SNRIs, and Tricyclic/Tetracyclic Antidepressants have been the standard treatment for years, ketamine offers a novel approach that goes beyond symptom management, targeting the root causes of depression.

Ketamine, often known as a rapid-acting antidepressant, has generated significant interest in the field of mental health. This article delves into the recent findings from a study titled "Ketamine induced synaptic plasticity operates independently of long-term potentiation" by Michelle K. Piazza, Ege T. Kavalali, and Lisa M. Monteggia. We'll explore the study's key points in a simplified manner to help you grasp how ketamine affects brain function and its implications for treating depression.

Anxiety disorders are among the most common mental health issues worldwide, affecting millions of individuals and significantly impairing their quality of life. Traditionally, benzodiazepines (benzos) and selective serotonin reuptake inhibitors (SSRIs) have been the primary treatments. However, these medications often come with significant drawbacks, including dependency, withdrawal symptoms, and delayed onset of action.

At Well3, we believe in providing access to healthcare tools before it's too late. Individuals should be able to access weight loss medications before becoming overweight, and mental health treatments before enduring years of depression and anxiety. We advocate for proactive healthcare, ensuring you receive the necessary tools to address health issues early, before they escalate.